drugset / Trial / NCT00536016
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the way and rate that the study medication, JSM6427 a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated from the body when it is given as a single dosage strength by injection into the eye. Repeated dosages will also be given to determine the highest safe dose.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JSM6427 | Unknown | 1.5 mg/ml | Intravitreal |
| Subject | JSM6427 | Unknown | 3 mg/ml | Intravitreal |
| Subject | JSM6427 | Unknown | 7.5 mg/ml | Intravitreal |
| Subject | JSM6427 | Unknown | 15 mg/ml | Intravitreal |